NeurologyLive® Mind Moments® cover art

All Episodes

NeurologyLive® Mind Moments® — 186 episodes

#
Title
1

165: Addressing Cognitive Decline in Parkinson Disease

2

164: Tremor vs Dyskinesia: Practical Bedside Clues for Clinicians

3

163: The Clinical Reality of Seronegative Myasthenia Gravis

4

Key Challenges Facing Neurology in the Year Ahead

5

162: Breaking Down INFUSE Trial Data and Real-World Eptinezumab Use

6

161: Clinical Takeaways From 2026 International Stroke Conference

7

160: Early Pathology, Biomarkers, and the Next Phase of DMD Care

8

Special Episode: The 2026 AHA/ASA Guideline for Early Management of Acute Ischemic Stroke

9

159: Key Practice Takeaways From the New AAN Functional Seizure Guidelines

10

158: Bexicaserin, the PACIFIC Trial, and Treating Developmental Epileptic Encephalopathies

11

157: Clinical Advances and Unanswered Questions in Narcolepsy

12

156: Building Better Mood and Behavior Care for Parkinson Disease

13

155: Understanding Variability in Infantile Spasms Care

14

154: NEALS 2025: Takeaways That Matter for ALS Care

15

153: Overviewing the 2025 Alzheimer's Association's Blood-Based Biomarker Guidelines

16

152: Building Safer, Smarter, and More Personalized Epilepsy Care

17

151: ECTRIMS 2025 Debrief: Precision MS & What’s Next with Daniel Ontaneda

18

150: Rethinking Parkinson’s Care: Prevention, Equity, and Access to Treatment

19

Special Episode: Understanding Fremanezumab's Expanded Indication in Pediatric Migraine

20

149: Overviewing Consensus Guidelines to Standardize Gene Therapy Care in Duchenne

21

148: Navigating Transition: Supporting Young Adults With Epilepsy Into Adult Care

22

147: Improving Quality of Life in Movement Disorders Through Nonmotor Symptom Management

23

146: Overviewing Donanemab’s New Dosing Regimen: Lowering ARIA Risk in Alzheimer Care

24

Breaking Down the FDA’s Latest Migraine Therapy Approvals with Dr. Stewart Tepper

25

145: Rewiring Stroke Recovery: What the Glymphatic System Can Teach Us

26

144: Differentiating Dravet and Lennox-Gastaut: Diagnosis, Research, and What’s Ahead

27

143: Bemdaneprocel and the Future of Cell Therapy in Parkinson Disease

28

142: World MS Day: Raising Awareness, Evolving Care, and Empowering Patients

29

141: Refining TSC Care: Phenotyping, Clustering, and Clinical Impact

30

140: Down Syndrome and Alzheimer’s: Clinical Trials, Equity, and Patient-Centered Progress

31

139: Sleep and Seizures: Emerging Insights From AAN 2025

32

138: Training the Next Generation of Neurology Nurse Practitioners

33

Special Episode: What Apomorphine Infusion Approval Means for Parkinson Disease Care

34

137: Advancing Neuromuscular Care and Research

35

Special Episode: FDA Approves Tenecteplase for Acute Ischemic Stroke

36

136: Raising Epilepsy Awareness for Purple Day

37

135: Invaluable Role of Social Support in Narcolepsy and Idiopathic Hypersomnia Care

38

134: Previewing the 2025 ACTRIMS Forum

39

133: Clinical Guidance on Neurostimulation for Lennox-Gastaut Syndrome

40

132: Aiding Diagnosis of Synucleinopathies Through SAAmplify-aSYN Biomarker Test

41

131: Neurology Unwrapped: 2024’s Most Intriguing Conversations

42

130: The Promise Behind Cell Therapy Approaches in Epilepsy

43

129: Implications of the 2024 AASM Guidelines for Restless Legs Syndrome

44

128: Machine Learning Algorithms to Predict Seizure Control in Epilepsy Surgery

45

127: Adapting Neuromuscular and Electrodiagnostic Medicine Education for Modern Learners

46

Special Episode: FDA Approves Sodium Oxybate for Pediatric Narcolepsy

47

126: Therapeutic Potential of ATH434 in Multiple System Atrophy

48

125: Understanding Major Changes to New McDonald Criteria for Multiple Sclerosis

49

124: Therapeutic Updates and Progress in Treating Becker Muscular Dystrophy

50

123: Previewing Cleveland Clinic's Epilepsy Summit

51

122: RNA Therapeutics, Mivelsiran, and Treating Alzheimer Disease

52

121: Understanding the Potential Cardiovascular Benefits of Low-Sodium Oxybate

53

115: Expanding Access to Ublituximab and AntiCD20s for Multiple Sclerosis

54

120: Improving Gait in Multiple Sclerosis Through the Neural Sleeve

55

119: Utilizing the Syn-One Test to Diagnose Parkinson Disease

56

Special Episode: FDA Approves Donanemab for Early Symptomatic Alzheimer Disease

57

118: Gaining Patient Perspectives on Impact of Narcolepsy

58

117: 2024 Consortium of Multiple Sclerosis Centers Annual Meeting Highlights

59

116: Understanding Vorasidenib's Therapeutic Benefit on Neurocognition, Seizure Control in Diffuse Gliomas

60

114: Phase 3 PHOENIX Study, AMX0035, and Amylyx's Future Drug Development

61

Special Episode: FDA Approval of Diazepam Buccal Film for Pediatric Seizures

62

113: Lessons Learned in Alzheimer Drug Development

63

112: Exploring Dimethyl Fumarate to Treat Friedreich Ataxia

64

Special Episode: FDA Approval of Givinostat for Duchenne Muscular Dystrophy

65

111: Reviewing ACTRIMS 2024

66

110: Differential Diagnosis of Sleep Disorders and Hypersomnias

67

109: AB126, Exosomes, and Cerebroprotection for Stroke

68

108: Advancing the Genetic Pool of Parkinson Disease

69

107: Revealing Mechanisms of Sudden Unexplained Death in Toddlers

70

106: Potential Role of Stathmin-2 in Amyotrophic Lateral Sclerosis

71

105: Recapping Conversations in Neurology From 2023

72

104: Effects of Once-Nightly Sodium Oxybate on Narcolepsy Type 1 and 2

73

103: Advancing Epilepsy Care and Seizure Localization in Pediatrics

74

102: Potential of Gamma Sensory Stimulation in Alzheimer Disease

75

Special Episode: FDA Greenlights Vamorolone for Duchenne Muscular Dystrophy

76

101: Ways to Enhance Neuromodulation in Parkinsonism

77

Special Episode: FDA Approves Zilucoplan for Myasthenia Gravis

78

100: 2023 ECTRIMS-ACTRIMS Meeting Highlights

79

99: Understanding AMX0035's Potential in Progressive Supranuclear Palsy

80

98: Uncovering Phenotypical Features of Narcolepsy Type 1

81

97: Identifying Gaps in Access to Parkinson Disease Care

82

96: Complexities With Cognitive Screening in Primary Care Settings

83

Special Episode: Addition of Valbenazine to Treat Huntington Disease Chorea

84

95: Expanding Potential for Long-Term Treatment in SMA

85

94: The Discussion Surrounding Lecanemab's Approval for Alzheimer Disease

86

93: Caring for Women With Parkinson Disease

87

92: Highlights From the 2023 CMSC, SLEEP, AHS, and ATMRD Annual Meetings

88

Special Episode: SRP-9001 Approved As First Gene Therapy for Duchenne Muscular Dystrophy

89

91: Assessing the Landscape of Sleep Disorder Care

90

90: Raising Stroke Awareness and Improving Clinical Care

91

89: Potential of CNM-Au8 Gold Nanocrystals to Treat ALS

92

88: 2023 AAN Annual Meeting Highlights

93

Special Episode: Tofersen Approved for SOD1 ALS

94

87: Severe Multiple Sclerosis and the CASA-MS Study

95

86: Pimavanserin and Atypical Antipsychotics to Treat Parkinson Disease Psychosis

96

85: Impact of Narcolepsy on Social Relationship Health in Adolescents

97

Special Episode: Trofinetide Approved for Rett Syndrome

98

84: Parkinson Disease Education for Community Providers

99

83: The ARISE Study and Using DMTs in RIS

100

82: Managing Seizures After Ischemic Stroke

101

81: Widening the Therapeutic Window in Parkinson Disease

102

80: Advancing Treatment for Rare Neuromuscular Disorders

103

Special Episode: Lecanemab Approved for Alzheimer Disease

104

79: A New Monoclonal for Alzheimer Disease

105

78: A Virtual Reality Platform for Parkinson Disease

106

77: A New Era of Myasthenia Gravis Treatment

107

76: ECTRIMS 2022 and the Latest in MS Advances

108

75: Focusing on the Future of Neurology

109

74: Prescription Digital Therapeutics for Insomnia

110

73: The Role of Palliative Care in Neurology

111

72: Updates in Epilepsy Treatment

112

71: Pediatric Sleep and School Start Times

113

70: Raising Awareness of Acute Flaccid Myelitis

114

69: The Widespread Effects of DMT Waste in Multiple Sclerosis

115

68: Updates in Essential Tremor Care

116

67: Mental Health and Advocacy in Pediatric Migraine

117

66: 2022 SLEEP Annual Meeting Highlights

118

Special Episode: Aducanumab and Anti-Amyloid-ß, One Year Later

119

65: 2022 CMSC Annual Meeting Highlights

120

64: Genetics, Advocacy, and Big Data in ALS

121

63: Moving Migraine Toward Personalized Care

122

62: Advanced Therapeutics in Parkinson and Movement Disorders

123

61: 2022 AAN Annual Meeting Highlights

124

Special Episode: Ganaxolone Approved for CDD, Fenfluramine Approved for LGS

125

60: Improving Care and Raising Awareness for NMOSD

126

Special Episode: Heart Health in Narcolepsy

127

59: AASM's Push to End Daylight Saving Time

128

58: Addressing Parkinson Disease Virtually With Prime PD

129

57: Invisible Symptoms: Cognition and MS

130

56: Epstein-Barr Virus's Relationship With Multiple Sclerosis

131

55: Treating Headache in the Emergency Department

132

Special Episode: Daridorexant Approved for Insomnia

133

54: The Shortage of Neurologists

134

53: A Landmark Year for Alzheimer Disease

135

52: Treating Pediatric Migraine

136

51: The State of Sleep Medicine

137

50: Genetic Testing for Huntington Disease

138

49: Altering the View of MS With a Topographical Model

139

48: RapidAI's Effect on Stroke Imaging

140

47: Incorporating Physical Therapy Into MS Care

141

46: Tackling Barriers to Migraine Care

142

45: Small Victories: Advancing Care in Parkinson Disease

143

44: AHA/ASA Updates to the Stroke Care Model

144

43: Is Telehealth Here to Stay for Alzheimer Disease Care?

145

42: The Importance of Sleep for Overall Health

146

41: Consensus MRI Guidelines for MS

147

40: SLEEP 2021: Topline Data, Telemedicine, and Takeaways

148

39: A Controversial FDA Decision

149

38: Advancing MS Care and Awareness

150

37: The Impact of Awareness Efforts in ALS

151

36: Zavegepant and the Gepant Class for Migraine Care

152

35: Highlights From the AAN Annual Meeting

153

34: Hope and the Huntington Disease Pipeline

154

33: Problem Recognition: Cerebral Palsy Diagnosis

155

32: The Gaps in Migraine Care for Women

156

31: The Pipeline Pendulum in Parkinson Disease

157

30: Cognitive Behaviorial Therapy for Insomnia

158

29: Developing A Seizure Action Plan

159

28: The Multiple Sclerosis Patient Journey

160

27: Short, Sudden, Strange, Similar Spells

161

26: Digital Approaches to Comprehensive Care in MS

162

25: 2020 Wrap Up: Silver Linings

163

24: Aducanumab and Alzheimer Disease Clinical Trials

164

23: Real-World Acute Migraine Care

165

22: Capitalizing on Collaboration in Neurology Care

166

21: How Social Isolation Can Affect Disease Severity

167

20: Taking Steps to Advance Sleep Care

168

19: The Vascular Implications of Alzheimer Disease

169

18: Preventing Tonic-Clonic Seizures in Refractory Epilepsy

170

17: The Metamorphosis of Migraine: Discovery and Development

171

16: Personalizing Our Approach to Medication Adherence in Parkinson Disease

172

15: A New Approval: The SMA Treatment Landscape

173

14: Trends in the Alzheimer Clinical Pipeline

174

13: Sequencing SNPs in Huntington Disease

175

12: Masculinity and Multiple Sclerosis

176

11: Exploring the Link Between Stroke and COVID-19

177

10: Neurology and COVID-19: Perspectives From the Front Line

178

9: Innovation in the Parkinson Disease Pipeline

179

8: Adapting Neurologic Care During the COVID-19 Pandemic

180

7: No Relief: Rising MS Drug Prices

181

6: Time Is Brain: Why EMS Transport Protocols Matter

182

5: Gut Bacteria and the Brain: An Evolving Role in Epilepsy

183

4: Only the Beginning: Advancing Migraine Treatment

184

3: Using Technology to Broaden Stroke Care

185

2: Alzheimer Disease Update: Is Amyloid Really Dead?

186

1: State of CBD: Not All Cannabidiol Is Created Equal